Muvalaplin, an oral, once-daily treatment that inhibits lipoprotein(a) formation via a novel mechanism, achieved positive results in a 12-week Phase 2 ...

MELBOURNE, Australia I November 19, 2024 I Neurizon Therapeutics Limited (ASX: NUZ & NUZOA) (“Neurizon” or “the Company”), a clinical-stage biotech company advancing treatments for neurodegenerative ...

BOSTON, MA, USA I, 2024 I LAPIX Therapeutics, Inc. (“LAPIX”), a clinical-stage biopharmaceutical company focused on developing novel, orally ...

OXFORD, UK I November 19, 2024 I Theolytics, a clinical-stage biotechnology company developing next-generation oncolytic immunotherapies, has dosed the first patient in its Phase I/IIa multi-centre, ...

LONDON, UK I1, 2024 I Vicebio Ltd ("Vicebio"), a biopharmaceutical company pioneering next-generation vaccines for life-threatening respiratory ...

SAN FRANCISCO, CA, USA I November 18, 2024 I Nektar Therapeutics (Nasdaq: NKTR) today announced its oral presentation highlighting preclinical data on NKTR-422 at the 2024 American College of ...

GIGA-2339 contains more than 1,000 fully human recombinant anti-HBV antibodies and is the first recombinant polyclonal therapeutic in development to treat and functionally cure chronic HBV infection ...

Investigational subcutaneous pembrolizumab and berahyaluronidase alfa, in combination with chemotherapy, demonstrates noninferior pharmacokinetics compared to intravenous KEYTRUDA in combination with ...

NORTH CHICAGO, IL, USA I 18, 2024 I AbbVie (NYSE: ABBV) today announced the European Commission (EC) granted marketing authorization for ELAHERE® ...

Monthly tobevibart and elebsiran combination achieves rapid 100% virologic suppression at Week 24, sustained through Week 60 – ...

SHANGHAI, China I November 19, 2024 I Epigenic Therapeutics, a leading biotechnology company dedicated to developing next-generation gene modulation therapy, today announced that it has received ...